Scarica l'app Stockscreener
9.36
0.21%
-0.02
Dopo l'orario di chiusura:
9.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GRFS Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Grifols Sa Adr Borsa (GRFS) Ultime notizie
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols, S.A.American Depositary Shares (Nasdaq:GRFS) Stock Quote - FinancialContent
Validea Joseph Piotroski Strategy Daily Upgrade Report10/10/2025 - Nasdaq
Arm Holdings PLC ADRhedged (BATS:ARMH) Short Interest Down 33.3% in September - Defense World
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
GRDLY Stock Price, Quote and News - Markets.com
Grifols (NASDAQ:GRFS) Share Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.
Grifols Announces Interim Dividend for 2025 - The Globe and Mail
CNH Industrial NV (NYSE: CNH) Stock Forecast: Bearish Sentiment Points To -15.21% Downside In 2025 - stocksregister.com
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - Benzinga
Oppenheimer Asset Management Inc. Acquires 23,980 Shares of Grifols, S.A. (NASDAQ:GRFS) - Defense World
ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - The Globe and Mail
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
Grifols S.A. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Investing in Grifols SA ADR (GRFS): What You Must Know - knoxdaily.com
Fox Corporation [FOX] stock was sold by MURDOCH KEITH RUPERT at the price of US$3.08 million - knoxdaily.com
6 undervalued stocks with low beta - Morningstar
Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar Canada
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - PR Newswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Grifols, S.A. - GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Grifols, - GlobeNewswire
GRFS Stock Quote Price and Forecast - CNN
BreakingviewsShort attack intensifies Grifols’ health problem - Reuters
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - PR Newswire
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - PR Newswire Canada
8 Newly Undervalued 5-Star Stocks - Morningstar
Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 - PR Newswire
Grifols Class B: Buy The Recovery In The U.S. Plasma Business (NASDAQ:GRFS) - Seeking Alpha
Grifols SA Share Price ADR each Representing 1 Non Voting B Share - Hargreaves Lansdown
Grifols, S.A.: Target Price Consensus and Analysts Recommendations | GRF | ES0171996087 - MarketScreener
Grifols SA: Shareholders Board Members Managers and Company Profile | ES0171996012 - MarketScreener
These European companies benefit from high health-care prices in the U.S. - MarketWatch
How International Is Your Foreign-Stock Fund? - Morningstar
GRFS or ORINY: Which Is the Better Value Stock Right Now? - Yahoo News Canada
GRF Stock Price and Chart — BME:GRF - TradingView
Top 75 Healthcare Dividend Stocks To Invest In - Insider Monkey
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo
Grifols, S.A. (GRFS) Stock Price, News, Quote & History - Yahoo
Hologic (HOLX) to Divest Blood Screening Business to Grifols - Yahoo Finance
Melnyk sets sights on insolvent Hemosol - The Globe and Mail
0.68%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):